Enveric Biosciences, Inc. (ENVB)
- Previous Close
0.4152 - Open
0.4233 - Bid 0.2964 x 200
- Ask 0.4871 x 200
- Day's Range
0.3700 - 0.4233 - 52 Week Range
0.3700 - 2.9200 - Volume
15,945,139 - Avg. Volume
1,063,498 - Market Cap (intraday)
3.365M - Beta (5Y Monthly) 0.50
- PE Ratio (TTM)
-- - EPS (TTM)
-3.4900 - Earnings Date Nov 11, 2024 - Nov 15, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Apr 23, 2008
- 1y Target Est
8.32
Enveric Biosciences, Inc., a biotechnology company, engages in the development of small-molecule therapeutics for the treatment of anxiety, depression, and addiction disorders. Its lead product candidates are EB-002, an active metabolite of psilocybin, which is in preclinical development stage for the treatment of anxiety disorders; and EB-003 that is in preclinical development stage for the treatment mental health. The company also focuses on the development of cannabinoid conjugate molecules for the treatment of pain and cancer. Enveric Biosciences, Inc. is headquartered in Naples, Florida.
www.enveric.comRecent News: ENVB
View More
Performance Overview: ENVB
Trailing total returns as of 10/15/2024, which may include dividends or other distributions. Benchmark is
.YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ENVB
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ENVB
View MoreValuation Measures
Market Cap
3.68M
Enterprise Value
-3.40M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
0.68
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-80.50%
Return on Equity (ttm)
-206.10%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-10.59M
Diluted EPS (ttm)
-3.4900
Balance Sheet and Cash Flow
Total Cash (mrq)
3.5M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-9.04M
Research Analysis: ENVB
View MoreCompany Insights: ENVB
ENVB does not have Company Insights